



HAL
open science

High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area

Basma Abdi, Aude Laetitia Ndoadoumgue, Siham Djebara, Karen Zafilaza, Romain Palich, Stéphane Marot, Luminata Schneider, Marc Wirden, Sophie Seang, Yasmine Dudoit, et al.

► To cite this version:

Basma Abdi, Aude Laetitia Ndoadoumgue, Siham Djebara, Karen Zafilaza, Romain Palich, et al.. High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area. *Journal of Infection*, In press, 10.1016/j.jinf.2022.05.036 . hal-03691744

HAL Id: hal-03691744

<https://hal.science/hal-03691744>

Submitted on 9 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Title**

2 High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area.

3 **Running title**

4 Seroprevalence of SARS-CoV-2 in HIV patients

5

6

7 Basma ABDI¹, Aude Laetitia NDOADOUMGUE², Siham DJEBARA³, Karen ZAFILAZA¹, Romain PALICH³, Stéphane MAROT¹, Luminata
8 SCHNEIDER³, Marc WIRDEN¹, Sophie SEANG³, Yasmine DUDOIT³, Elisa TEYSSOU¹, Roland TUBIANA⁴, Cathia SOULIE¹, Marc
9 Antoine VALANTIN³, Christine KATLAMA³, Vincent CALVEZ¹, Lambert ASSOUMOU², Anne-Geneviève MARCELIN¹, Valérie
10 POURCHER³

11

12 ¹Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Hôpital Pitié
13 Salpêtrière, Laboratoire de virologie, Paris, France.

14

15 ²Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.

16

17 ³Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Hôpital Pitié
18 Salpêtrière, Service des Maladies infectieuses et tropicales, Paris, France.

19

20 **Corresponding author**

21 Dr Basma ABDI, Laboratoire de Virologie-CERVI, Hôpital Pitié Salpêtrière 45-83 Bd de l'hôpital 75013 Paris, France. Phone: 33 1 84 82 80
22 44. Fax: 33 1 42 17 74 11.

23 Email: basma.abdi@aphp.fr

24

25 **Abstract**

26 **Objectives**

27 We studied the kinetics of SARS-CoV-2 antibodies and identified the associated risk factors with the presence of these antibodies.

28 **Methods**

29 In this longitudinal cohort study, we included all PLWHIV. Samples were tested for IgG targeting the nucleocapsid (N) and all positive samples
30 were tested for IgG targeting the spike (S) and IgA targeting S.

31 **Results**

32 1,901 PLWHIV were included: 64.4% male, median age: 53 years (44-60). At inclusion, 254 (13.4%, 95% CI 11.9, 15.0) had positive IgG anti-N.
33 Levels of IgG anti-N, IgG anti-S and IgA anti-S were 3.95 (standard error: 0.16), 199.4 BAU/mL (21.7) and 3.14 (0.21), respectively. Over one
34 year, levels of IgG anti-N and anti-S decreased significantly (-2.83 p<0.0001 and -94.9 BAU/mL p= 0.0010, respectively), while IgA level increased
35 significantly (+2.97 p=0.0032). Multivariable analysis showed that Sub-Saharan African patients were more likely to have positive IgG anti-N in
36 comparison with other patients (OR:4.78 (95% CI 3.39, 6.73), p<0.0001), while active smoking was a protective factor (OR: 0.57 (95% CI 0.36,
37 0.90), p=0.0176).

38 **Conclusion**

39 We showed in these PLWHIV a high SARS-CoV-2 seroprevalence. A higher seroprevalence was observed in sub-Saharan Africa patients, probably
40 due to socioeconomic status and a lower seroprevalence was observed in active smokers.

41 **Key-words**

42 SARS-CoV-2, COVID-19, seroprevalence, HIV, humoral immune response, risk factors.

43

44 Dear Editors,

45 As reported in this journal, a recent study in South Africa suggest that HIV is not a risk factor for moderate or severe COVID-19 disease neither
46 is it a risk factor for mortality¹ However other studies described that HIV could be associated with a similar or a higher risk of acquiring
47 COVID-19 and/or worse outcomes^{2,3}. To date, no longitudinal studies have been conducted in PLWHIV. Thus, we aimed to determine the
48 SARS-CoV-2 seroprevalence in our PLWHIV and to identify factors potentially associated with COVID-19 infection, and then to evaluate the
49 kinetics of anti-SARS-CoV-2 antibodies.

50

51 Our study is a longitudinal prospective cohort conducted between April 2020 and September 2021. All HIV-1 patients followed in the Pitié-
52 Salpêtrière hospital were invited to participate in this study. Residual plasma samples obtained from plasma HIV-RNA viral load measurements
53 were used to perform SARS-COV-2 serologies.

54 IgG was measured using the Abbott Alinity instrument. It is a chemiluminescent microparticle immunoassay for semi-qualitative detection of
55 IgG against nucleoprotein (N) and quantitative detection of IgG against the receptor-binding domain (RBD) of spike (S) protein. IgA against
56 the S1 domain of the S protein was measured using enzyme-linked immunosorbent assays (ELISA, EuroImmun). At inclusion, all plasma
57 samples were screened for IgG anti-N and all samples that were confirmed positive for IgG anti-N were tested to detect IgG anti-S and IgA
58 anti-S. Patients with positive serology were evaluated at 6 and 12 months (M).

59 Univariable and multivariable logistic regression models were used to assess factors associated with the risk of a positive serology at baseline.
60 We used a multiple imputation approach with Fully Conditional Specification method to fill in missing data. The change from baseline in
61 antibodies levels overtime were compared using mixed models for repeated measures with random effects and unstructured covariance matrix.

62

63 A total of 1,901 PLWHIV were enrolled in the study. 64.4% of them were male with median age of 53 years (44-60). Only 57 patients reported
64 previous COVID-19 infection without any complications. Among the participants, 26.6% were active smokers and 38.3% were from sub-
65 Saharan Africa.

66 At inclusion, 254 patients were seropositive, corresponding to a seroprevalence rate in PLWHIV of 13.4% (95% IC 11,9%, 15%). Median age
67 was 50 years (43-57), 53.5% men, 72.7% Sub-Saharan African, only 37 previous COVID-19 infection and 10.8% were active smokers. The
68 main characteristics of the study population are summarized in table 1.

69 Among seropositive patients, 88.2% and 64.1% had positive IgG anti-S and IgA anti-S respectively at baseline. The mean levels of antibody
70 concentrations were 3.95 (Standard error (SE) 0.16) for IgG anti-N, 199.4 BAU/mL (SE 28.3) for IgG anti-S and 3.14 (SE 0.21) for IgA anti-
71 S. At M6, 51.9%, 87.3% and 75.4% patients had positive IgG anti-N, IgG anti-S and IgA anti-S respectively. At M12, 35.2%, 87.6%, and
72 81.2% patients had positive IgG anti-N, IgG anti-S and IgA anti-S respectively. Over one year, levels of IgG anti-N and anti-S decreased

73 significantly (-2.83 (SE 0.20) $p < 0.0001$ and -94.9 BAU/mL (SE 28.3) $p < 0.0001$ respectively), while IgA anti-S level increased significantly
74 (+2.97 (SE 0.95) $p < 0.0001$).

75 Univariable et multivariable logistic regression analyses were performed to assess independent factors associated with positive serology at
76 baseline (Table 2). Fourteen factors were retained for the multivariable analysis showed that the geographical origin and smoking were
77 independently associated with positive SARS-CoV-2 antibodies. Sub-Saharan African patients were more likely to have positive IgG anti-N in
78 comparison with patients originating from France and other countries (OR: 4.78 [95% CI 3.39;6.73], $p < 0.0001$), while active smoking was a
79 protective factor (OR: 0.57 [95% CI 0.36; 0.90], $p = 0.0176$).

80

81

82 To our knowledge, this is the first study evaluating the seroprevalence and assessing the kinetics of SARS-CoV-2 antibodies during one year
83 in the HIV population. Our findings show a higher seroprevalence of SARS-CoV-2 in PLWHIV in comparison to that reported in general
84 population in France in the same period⁴. This result could be explained by social and behavioural determinants of health associated with
85 COVID-19 transmission in different communities especially in PLWHIV. Indeed, we found a higher seroprevalence of SARS-CoV-2 in African
86 Sub-Saharan HIV patients, which may reflect social inequalities in health and healthcare in France for people of sub-Saharan African origin.
87 We showed that levels of IgG anti-N and IgG anti-S decreased significantly while levels of IgA anti-S increased significantly over one year.
88 Our results reinforce previous studies of evolution of antibody immunity to SARS-CoV-2 showing the decrease of antibody levels with time⁵⁻

89 ⁷. Previous works have shown that anti-RBD IgA levels decreased in a less proportion compared to the anti-RDB IgG levels over a time period
90 of 6 to 9 months ⁷. Antibody kinetics suggest that HIV patients don't exhibit an efficient immune response in case of virus re-exposure.
91 However, direct conclusions about protective immunity cannot be made only on the basis of humoral immunity. Other investigations in memory
92 B and T cells are needed.

93 We showed also that active smoking was associated with a lower rate of IgG anti-N antibodies. Our result is in line with other studies showing
94 that active smoking was associated with a lower rate SARS-CoV-2 antibodies and supporting the role of nicotine as protective for SARS-CoV-
95 2 infection ^{4,8}. Many authors hypothesize that this protective role is associated with the nicotine regulation of angiotensin-converting enzyme-
96 2 receptor expression which is involved in SARS-CoV-2 entry ⁸. However, data on whether COVID-19 has a greater incidence in non-smokers
97 is still contradictory and the causal role of tobacco in lung cancer and chronic obstructive pulmonary disease should not encourage smoking to
98 limit the risk of developing COVID-19.

99 In conclusion, the higher seroprevalence observed in sub-Saharan Africa patients highlights the need of an implementation of health and
100 prevention system taking care of vulnerable people especially PLWHIV. More investigations are needed to understand the association between
101 smoking and COVID-19.

102

103

104 **Funding**

105 This work was supported by the ANRS-MIE and the EMERGEN consortium.

106

107 **Acknowledgements**

108 We thank the clinical research team (Aida Zarhrate- Ghoul, Soumeya Hammal).

109

110 **Transparency declarations**

111 None to declare

112

113 **Authors contribution**

114 Conceptualization, BA., VP., A.G.M., LA. and VC; Methodology, ALN., LA., BA., VP. and A.G.M.; Software, ALN. and LA.; Validation,
115 BA., VP., A.G.M., LA. and VC.; Formal Analysis, ALN. and LA.,; Investigation, SD., RP., KZ., SM., ET., CS., MAV., CK., LS., RT.,MW.
116 and SS. ; Data Curation, BA., ALN., LA.; Writing – Original Draft Preparation, BA., VP., ALN. and LA.; Writing – Review & Editing, all
117 authors reviewed and accepted the final version of the article.; Supervision, VP., A.G.M., VC. and LA.; Project Administration, BA., VP. and
118 YD.; Funding Acquisition, A.G.M., VC. and VP.

119 **References**

- 120 1 Venturas Jacqui, Zamparini Jarrod, Shaddock Erica, Stacey Sarah, Murray Lyle, Richards Guy A., et al. Comparison of outcomes in HIV-
121 positive and HIV-negative patients with COVID-19. *J Infect* 2021;**83**(2):217–27. Doi: 10.1016/j.jinf.2021.05.020.
- 122 2 Lee Kai Wei, Yap Sook Fan, Ngeow Yun Fong, Lye Munn Sann. COVID-19 in People Living with HIV: A Systematic Review and Meta-
123 Analysis. *Int J Environ Res Public Health* 2021;**18**(7):3554. Doi: 10.3390/ijerph18073554.
- 124 3 Brown Lillian B., Spinelli Matthew A., Gandhi Monica. The interplay between HIV and COVID-19: summary of the data and responses to
125 date. *Curr Opin HIV AIDS* 2021;**16**(1):63–73. Doi: 10.1097/COH.0000000000000659.
- 126 4 Carrat Fabrice, de Lamballerie Xavier, Rahib Delphine, Blanché Hélène, Lapidus Nathanael, Artaud Fanny, et al. Antibody status and
127 cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk
128 factors: a multicohort study. *Int J Epidemiol* 2021:dyab110. Doi: 10.1093/ije/dyab110.
- 129 5 Gaebler Christian, Wang Zijun, Lorenzi Julio C. C., Muecksch Frauke, Finkin Shlomo, Tokuyama Minami, et al. Evolution of antibody
130 immunity to SARS-CoV-2. *Nature* 2021;**591**(7851):639–44. Doi: 10.1038/s41586-021-03207-w.
- 131 6 Dan Jennifer M., Mateus Jose, Kato Yu, Hastie Kathryn M., Yu Esther Dawen, Faliti Caterina E., et al. Immunological memory to SARS-
132 CoV-2 assessed for up to 8 months after infection. *Science* 2021:eabf4063. Doi: 10.1126/science.abf4063.
- 133 7 Ortega Natalia, Ribes Marta, Vidal Marta, Rubio Rocío, Aguilar Ruth, Williams Sarah, et al. Seven-month kinetics of SARS-CoV-2
134 antibodies and role of pre-existing antibodies to human coronaviruses. *Nat Commun* 2021;**12**:4740. Doi: 10.1038/s41467-021-24979-9.

135 8 Farsalinos Konstantinos, Barbouni Anastasia, Niaura Raymond. Systematic review of the prevalence of current smoking among hospitalized
136 COVID-19 patients in China: could nicotine be a therapeutic option? *Intern Emerg Med* 2020;**15**(5):845–52. Doi: 10.1007/s11739-020-02355-
137 7.
138

	All patients		n (%) / Median (IQR)	Seropositive SARS-CoV-2 (IgG anti-N)	n (%) / Median (IQR)
	N			N	
Age (years)	1901		53 (44-60)	254	50 (43-57)
Sex	1901	Female	677 (35.6%)	254	118 (46.5%)
		Male	1224 (64.4%)		136 (53.5%)
Country of origin	1892	France	865 (45.7 %)	253	47 (18.6%)
		Europe	80 (4.2%)		6 (2.4%)
		North Africa	77 (4.1%)		4 (1.6%)
		Sub Saharan Africa	724 (38.3%)		184 (72.7%)
		America	65 (3.5%)		6 (2.4%)
		Asia	81 (4.3%)		6 (2.4%)
Active smoking	1286	No	944 (73.4%)	166	148 (89.2%)
		Yes	342 (26.6%)		18 (10.8%)

BMI (kg/m²)	1838		24.9 (22.3-28.6)	243	27.5 (23.9-30.5)
Duration of HIV infection (years)	1900		17.0 (9.1-26.0)	254	14.6 (8.0-19.7)
Duration of ARV treatment (years)	1891		13.9 (7.5-22.2)	252	11.5 (6.5-18.9)
CD4 (cells/mm³)	1710		588 (429 - 772)	224	518 (381-670)
CD4/CD8	1698		0.93 (0.61 - 1.38)	223	0.87 (0.60-1.39)
HIV-1 RNA viral load (cp/ml)	1784	<50 (cp/ml)	1594 (89.4%)	234	202 (86.3%)
		>50 (cp/ml)	190 (10.6%)		32 (13.7%)
Previous COVID-19 infection	636	No	579 (91.0%)	90	53 (58.9%)
		Yes	57 (9.0%)		37 (41.1%)
ART regimen	1884	2 NRTI + 1 NNRTI	480 (25.5%)	248	73 (29.4%)
		2 NRTI + 1 INSTI	681 (36.2%)		100 (40.3)
		2 NRTI + 1 PI	144 (7.6%)		19 (7.7%)
		1 INSTI+1 NRTI	22 (1.2%)		0 (0.0%)
		1 INSTI+1 NNRTI	164 (8.7%)		16 (6.5%)
		Others	393 (20.9%)		40 (16.1%)

140 **Table 1: Patients characteristics at baseline**

141 Categorical variables were summarised with frequency and percentages whereas continuous variables were summarised with median and

142 interquartile range (IQR); N= number of patients ; ARV= Antiretroviral; ART = Antiretroviral therapy ; NRTI= Nucleoside Reverse

143 Transcriptase Inhibitor ; NNRTI= Non-Nucleoside Transcriptase Inhibitor ; PI= Protease Inhibitor ; INSTI= Integrase Strand Transfer Inhibitor.

			n	COVID-19	Univariate		Multivariate	
Variables	N				OR (95% CI)	p value	OR (95% CI)	p value
Age (years)	1901	<50	714	125 (17.5%)	1	<0.0001	1	0.6492
		>=50	1187	129 (10.9%)	0.57 (0.44, 0.75)		0.93 (0.67, 1.29)	
Sex	1901	Male	1224	136 (11.1%)	1	<0.0001	1	0.0666
		Female	677	118 (17.4%)	1.69 (1.29, 2.21)		0.74 (0.54, 1.02)	
Country of origin	1901	Others	1175	70 (5.9%)	1	<0.0001	1	<0.0001
		Sub Saharan Africa	726	184 (25.3%)	5.36 (3.99, 7.19)		4.78 (3.39, 6.73)	
Department	1901	Paris	919	118 (12.9%)	1	0.5978		
		Others	982	135 (13.8%)	1.08 (0.82, 1.42)			
BMI (Kg/m²)	1901	<30	1559	182 (11.7%)	1	<0.0001	1	0.2024
		>=30	342	71 (20.9%)	2.00 (1.47, 2.73)		1.25 (0.89, 1.75)	
Smoking	1901	No	1395	220 (15.8%)	1	<0.0001	1	0.0176
		Yes	506	34 (6.7%)	0.38 (0.25, 0.59)		0.57 (0.36, 0.90)	
Duration of HIV infection (years)	1901			14.6 (7.9 – 19.7)	0.97 (0.96, 0.98)	<0.0001	0.99 (0.95, 1.02)	0.4424
Duration of ARV treatment (years)	1901			11.5 (6.6 – 18.8)	0.97 (0.96, 0.99)	0.0003	1.01 (0.95, 1.07)	0.7988

Time on ongoing ARV therapy (years)	1901			1.5 (0.8 – 2.4)	0.94 (0.89, 1.01)	0.0757	1.01 (0.94, 1.08)	0.8653
CD4 (cells/mm³)	1901	<350	290	53 (18.3%)	1	0.0127	1	0.2357
		>350	1611	201 (12.5%)	0.64 (0.45, 0.91)		0.79 (0.53, 1.17)	
CD8 (cells/mm³)*	1901			612 (390 – 816)	0.80 (0.67, 0.96)	0.0179	0.87 (0.70, 1.06)	0.1695
CD4/CD8 ratio	1901			0.9 (0.6 – 1.4)	1.00 (0.97, 1.04)	0.8507		
HIV-1 RNA viral load (cp/ml)	1901	<50	1698	219 (12.9%)	1	0.1371	1	0.6097
		>50	203	34 (16.8%)	1.36 (0.91, 2.04)		1.12 (0.72, 1.75)	
Abacavir + Lamivudine	1901	No	1822	246 (13.5%)	1	0.2730		
		Yes	79	7 (9.2%)	0.64 (0.29, 1.41)			
Emtricitabine + Tenofovir	1901	No	1681	222 (13.2%)	1	0.6741		
		Yes	220	31 (14.3%)	1.09 (0.73, 1.64)			
Emtricitabine + Tenofovir-alafenamide	1901	No	1166	142 (12.2%)	1	0.0724	1	0.8820
		Yes	735	111 (15.2%)	1.28 (0.98, 1.68)		0.97 (0.65, 1.45)	
Efavirenz	1901	No	1837	245 (13.4%)	1	0.9791		
		Yes	64	8 (13.3%)	0.99 (0.47, 2.10)			

Etravirine	1901	No	1844	248 (13.5%)	1	0.3214		
		Yes	57	5 (8.9%)	0.63 (0.25, 1.58)			
Rilpivirine	1901	No	1395	182 (13.1%)	1	0.5510		
		Yes	506	71 (14.1%)	1.09 (0.81, 1.47)			
Doravirine	1901	No	1827	242 (13.3%)	1	0.4686		
		Yes	74	12 (16.2%)	1.26 (0.67, 2.38)			
Nevirapine	1901	No	1839	248 (13.5%)	1	0.2479		
		Yes	62	5 (8.3%)	0.58 (0.23, 1.46)			
Atazanavir	1901	No	1829	243 (13.3%)	1	0.7509		
		Yes	72	10 (14.7%)	1.12 (0.56, 2.21)			
Darunavir	1901	No	1696	226 (13.4%)	1	0.9589		
		Yes	205	27 (13.3%)	0.99 (0.64, 1.53)			
Raltegravir	1901	No	1784	236 (13.3%)	1	0.6908		
		Yes	117	17 (14.6%)	1.11 (0.65, 1.90)			
Dolutegravir	1901	No	1352	196 (14.6%)	1	0.0196	1	0.4894
		Yes	549	57 (10.4%)	0.68 (0.50, 0.94)		0.87 (0.59, 1.28)	
Elvitegravir	1901	No	1786	239 (13.4%)	1	0.7289		

		Yes	115	14 (12.3%)	0.9 (0.51, 1.61)			
Bictegravir	1901	No	1540	196 (12.8%)	1	0.1249	1	0.3779

144

145 **Table 2: Factors associated with the risk of a positive serology SARS-CoV-2 (IgG anti-N) at baseline.**

146 Univariable and multivariable logistic regression models were used to assess factors associated with the risk of a positive serology (IgG anti-N) at
147 baseline. Multiple imputation approach with Fully Conditional Specification method was used to fill in missing data. Analyses were run on each
148 of the 10 data sets, including the imputed values, and the results were combined with Rubin's rules. Variables with a univariate p-value <0.20 were
149 included in the multivariable logistic regression model. The significance level of the p-value in the multivariable model was set at 0.05.